Subscribe

The Age of Curative Therapies – Moving Towards a Cost-Benefit Equilibrium?

Amid one of the most contentious periods of pricing battles in our history, the biopharma forecast shows an explosion of curative treatments coming to market.How do we evolve the health care business model to keep pace with–and finance– the drug discovery model? Hear from a payer CEO footing the bill, a biotech leader on the brink of a curative therapy for hemophilia and an economist with a brave new financing model as they share views on how the future will shake out.

Host: Jackie Kosecoff, Managing Partner, Moriah Partners ​

Discussion Leaders:
Jean-Jacques Bienaime, Chairman & CEO, BioMarin
Andrew Lo, Professor, MIT Sloan ​School of Management and Director, MIT Laboratory for​ Financial Engineering
Paul Markovich, CEO, Blue Shield of California

Share:

Jean-Jacques Bienaimé

Chairman & CEO
BioMarin

Mr. Bienaimé is currently the Chairman and Chief Executive officer at BioMarin. He joined the company in May 2005 as Chief Executive Officer and member of the board of directors, bringing with him over 25 years of experience in the biotechnology and pharmaceutical industries. Under his leadership, the market capitalization of BioMarin went from around $450 million in May 2005 to approximately $16 billion in Summer 2016. BioMar Full bio ›

Jackie Kosecoff

Managing Partner
Moriah Partners

Currently, Dr. Kosecoff is working in private equity to identify, select, mentor and manage health services and IT companies. From 2002 to 2012, Dr. Kosecoff was a senior executive inside UnitedHealth Group-PacifiCare. Dr. Kosecoff joined UnitedHealth Group as part of its acquisition of PacifiCare Health Systems in 2005.  At PacifiCare, Dr. Kosecoff served as Executive Vice President with responsibility for its specialty bu Full bio ›

Andrew Lo

Professor, MIT Sloan School of Management​
and Director, MIT Laboratory for Financial Engineering

Andrew W. Lo is the Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management, director of MIT’s Laboratory for Financial Engineering, and principal investigator at MIT's Computer Science and Artificial Intelligence Laboratory. His research interests include innovative approaches to healthcare financing and new statistical methods for incorporating patient preferences into the drug approval process and pre Full bio ›

Paul Markovich

President & CEO

Paul Markovich is president and CEO of Blue Shield of California, a 4-million-member nonprofit health plan, with more than $17 billion in annual revenue, that serves the state’s commercial, individual and government markets. Markovich assumed the position of CEO in January 2013. As president and CEO, Markovich leads Blue Shield’s mission to ensure Californians access to high-quality health care at an affordable price. In 20 Full bio ›

related interviews

The Age of Curative Therapies - Moving Towards a Cost-Benefit Equilibrium?

Jean-Jacques Bienaimé + Jackie Kosecoff + Andrew Lo + Paul Markovich

Amid one of the most contentious periods of pricing battles in our history, the biopharma forecast shows an explosion of curative treatments coming to market.How do we evolve the health care business model to keep pace with–and finance– the drug discovery model? Hear from a payer CEO footing the bill, a biotech leader on the brink of a curative therapy for hemophilia and an economist with a brave new financing model as they share views on how the future will shake out.